GlassScriptPhysician profile
Gregor John Koobatian
NPI 1609833730
$3,439.27
in general payments reported to CMS, 2019-2025
28 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $47.29 · 2021: $668 · 2022: $887 · 2023: $573 · 2024: $462 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $820.23 | 2019-2025 | Entyvio, Gattex |
| Abbvie INC. | $521.82 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $327.09 | 2020-2025 | Xifaxan |
| Boston Scientific Corporation | $247.89 | 2021-2025 | Captivator II, Spyglass |
| Pentax of America, INC. | $205.74 | 2022 | |
| Cook Medical LLC | $155.02 | 2024 | Echotip Insight |
| Allergan, INC. | $107.08 | 2019-2020 | |
| Medtronic, INC. | $104.39 | 2022 | |
| Qol Medical, LLC | $91.84 | 2021-2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $80.59 | 2021-2022 | |
| Gilead Sciences, INC. | $79.59 | 2022-2024 | |
| Ethicon US, LLC | $72.62 | 2025 | Linx Reflux Management System |
| Exact Sciences Corporation | $64.46 | 2023 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $59.87 | 2022 | |
| Celgene Corporation | $58.18 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $57.71 | 2022-2024 | Ibsrela |
| Redhill Biopharma INC. | $54.74 | 2021 | |
| Intercept Pharmaceuticals, INC. | $54.54 | 2019-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $52.36 | 2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $43.40 | 2023-2025 | Voquezna |
| Novo Nordisk INC | $33.63 | 2022-2025 | Wegovy |
| Fresenius Kabi USA, LLC | $30.32 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $26.03 | 2021 | |
| Mallinckrodt Hospital Products INC. | $22.37 | 2023 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $17.22 | 2023 | Dupixent |
| Portola Pharmaceuticals, LLC | $17.12 | 2019 | |
| Merck Sharp & Dohme LLC | $16.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregor Koobatian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.